Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8533158 | 0.75 | JAK2 (0.39) | VCPHCRTR2HCRTR1MTORCDK1 | |
| SCHEMBL2369924 | 0.74 | AGTR2 (0.48) | AGTR2HCRTR2HCRTR1 | |
| SCHEMBL8532537 | 0.71 | ALDH1A1 (0.45) | JAK2 | |
| SCHEMBL2540416 | 0.68 | CDK5 (0.42) | MTORCDK2 | |
| SCHEMBL2540569 | 0.66 | PIK3CA (0.34) | AGTR2MTORCDK2 | |
| SCHEMBL7470679 | 0.65 | HIF1A (0.41) | AGTR2 | |
| SCHEMBL22917166 | 0.65 | AGTR2 (0.70) | AGTR2HCRTR2HCRTR1 | |
| SCHEMBL23032510 | 0.63 | AGTR2 (0.65) | AGTR2HCRTR2HCRTR1 | |
| SCHEMBL84228 | 0.63 | NAMPT (0.35) | MTORCDK1CDK2 | |
| SCHEMBL8534040 | 0.62 | LMNA (0.40) | MTORJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835429-B2 | Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses | WYETH LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134959-A1 | PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | AGTR2 2457/4885VCP 2408/4885HCRTR2 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.